Genprex, Inc. (GNPX) Stock Price & Growth Analysis

New

Chrome Plugin Live! Redefine the way you read FinTwit 🚀 Install Now

You have successfully sign out

Genprex, Inc.

GNPX

NASDAQ

Unprofitable

EPS improving

Unprofitable

EPS improving

Biotechnology

Next Earning date - 21 May 2025

Biotechnology

Next Earning date - 21 May 2025

0.28USD

0.02 ( 6.87%)

Market Closed (as of Apr 25, 20:00 EDT)

Relative Strenght

Volume Buzz

-52%

Earning Acce

Yes

Dist 52w H.

93%

Overview Chart

Quote Panel

Updated April 27, 2025

1W 26.52 % 1M 5.05 % 3M -55.09 % 1Y -87.56 %

Key Metrics

Market Cap
6.88M
Shares Outstanding
24.15M
Share in Float
8.28M
Dividende
0

Earning Date
21 May 2025
Price Target
0.2848
Average Volume
4.17M
Beta
-0.386

Range
0.22-4.09
Industry
Biotechnology
Website
https://www.genprex.com
Sector
Healthcare

Quote Panel

Updated April 27, 2025

1W % 1M % 3M % 1Y %

Key Metrics

Market Cap
Shares Outstanding
Share in Float
Dividende

Earning Date
No Data
Price Target
Average Volume
Beta

Range
Industry
Website
Sector

Fundamentals

N/A

P/E Ratio

0.00x

P/S Ratio

0.70x

P/B Ratio

0.0

Debt/Equity

0.0%

Net Margin

$-5.3

EPS

How GNPX compares to sector?

P/E Ratio

Fundamentals

Relative Strength

GNPX

Sector

Top 5 RS in Group

Symbol	Company	RS	5-Day Perf.

Relative Strength

GNPX

Sector

Top 5 RS in Group

Symbol	Company	RS	5-Day Perf.

Forecast

$59M

NaN%

2025-Revenue

$1.25

-16%

2025-EPS

Analyst rating

Strong Sell

Sell

Buy

Neutral

Strong Buy

Buy

Price Target

NaN(-100.00%)

Number of analyst

Last analyst upgrade/downgrade

No Data Available

Forecast

Analyst rating

Last analyst upgrade/downgrade

Earnings Growth

YoY

Current

Estimates

Q1.23

N/A

-6.00
vs -4.80

Q2.23

N/A

-6.00
vs -4.40

Q3.23

N/A

-5.20
vs -5.20

Q4.23

N/A

-3.96
vs -0.12

Q1.24

N/A

-3.69
vs -6.00

Q2.24

N/A

-3.00
vs -6.00

Q3.24

N/A

-1.23
vs -5.20

Q4.24

N/A

-1.08
vs -3.96

Q1.25

N/A

-0.41
vs -3.69

Q2.25

N/A

-0.42
vs -3.00

Sales Growth

YoY

Current

Estimates

Q3.22

NA vs NA

Q4.22

NA vs NA

Q1.23

NA vs NA

Q2.23

NA vs NA

Q3.23

NA vs NA

Q4.23

23.2K vs NA

Q1.24

NA vs NA

Q2.24

NA vs NA

Q3.24

NA vs NA

Q4.24

-100%

NA vs 23.2K

Return on Equity

QoQ

Q1.23

-50%

-0.50
vs -0.29

Q2.23

-66%

-0.66
vs -0.50

Q3.23

-63%

-0.63
vs -0.66

Q4.23

-80%

-0.80
vs -0.63

Q1.24

-68%

-0.68
vs -0.80

Q2.24

-149%

-1.49
vs -0.68

Q3.24

-259%

-2.59
vs -1.49

Q4.24

-267%

-2.67
vs -2.59

Institutionnal Ownership

QoQ

Q1.22

54
vs 51

Q2.22

43
vs 54

-20%

Q3.22

46
vs 43

Q4.22

52
vs 46

13%

Q1.23

40
vs 52

-23%

Q2.23

39
vs 40

-2%

Q3.23

38
vs 39

-3%

Q4.23

33
vs 38

-13%

Earnings Growth

Latest News

prnewswire.com

8 hours ago

Genprex Selected to Present Trial Design of Acclaim-3 Clinical Trial Evaluating Reqorsa® Gene Therapy in Small Cell Lung Cancer at 2025 ASCO Annual Meeting

prnewswire.com

8 hours ago

Genprex Announces Research Collaborators' Abstract Published in Cancer Research Supplement Proceedings

prnewswire.com

8 hours ago

Genprex Collaborators to Present Positive Preclinical Data on the Use of Reqorsa® Gene Therapy for the Treatment of Lung Cancer at the 2025 AACR Annual Meeting

prnewswire.com

8 hours ago

Genprex Collaborators Selected to Present Positive Preclinical Data on Diabetes Gene Therapy at the 2025 American Diabetes Association 85th Scientific Sessions

prnewswire.com

8 hours ago

Genprex to Participate at BIO Europe Spring 2025

prnewswire.com

8 hours ago

Genprex Advances Diabetes Program with Addition of Research Focused on Non-Viral Delivery System

Company Description

0.28USD

N/A

0.00x

0.70x

0.0

0.0%

$-5.3

$59M

$1.25

Earnings Growth

Latest News

Company Description

0.28USD

$59M

$1.25

N/A

0.00x

0.70x

0.0

0.0%

$-5.3